Tessera Therapeutics Highlights Advancements Across its Gene Writing™ and Delivery Platforms
RNA Gene Writing™ platform demonstrates clinically relevant levels of in vivo rewriting in the genome of liver cells of non-human...
top of page
A L T I T U D E
Life Science Ventures
Companies in the News
Jan 6, 2023
eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin
Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated...
Dec 21, 2022
DNA Writing Goes Enzymatic, Encourages Pursuit of Bold Visions
The 1950s are widely recognized as one of the most important decades in biology. This is, in large part, due to the discovery of the...
Dec 19, 2022
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868
Phase 1b study designed to determine the safety and dose of NUV-868 in combination with olaparib or enzalutamide for the treatment of...
Dec 8, 2022
Federation Bio Administers First Dose in Phase 1 Clinical Trial
- Study will assess the safety, efficacy and engraftment of FB-001 for the treatment of enteric hyperoxaluria, a serious metabolic...
Nov 28, 2022
Escient Pharmaceuticals Announces $120 Million Series C Financing
Financing led by New Enterprise Associates (NEA), Abingworth and Forge Life Science Partners Proceeds support advancement of EP262 and...
Nov 23, 2022
Indigo Expands 2023 Biological Crop Protection Line with New Biofungicide
MEMPHIS, Tenn., Nov. 22, 2022 /PRNewswire/ -- Indigo Agriculture today announced the commercial launch of the industry's first biological...
Oct 11, 2022
Neumora Therapeutics Announces $112 Million Series B Financing
Proceeds to support the advancement of Neumora’s mission of building a leading global precision neuroscience company to revolutionize the...
Sep 14, 2022
eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin
Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 Drug...
bottom of page